Abstract
Background The use of vein grafts in coronary artery surgery is complicated by a high late restenosis rate resulting from the development of intimal hyperplasia, and accelerated atherosclerosis. TGFβ has been implicated in the process of intimal hyperplasia but the role of TGFβ driven Endothelial to mesenchymal is not fully understood. Here, we have investigated the hypothesis that arterial shear stress (flow) can trigger Endothelial to mesenchymal changes in venous ECs mediated by TGFβ / SMAD pathway in-vitro and ex-vivo and that a brief pretreatment of vein with Dexamethasone can suppress such changes.
Methods and Results Comparative reverse-transcriptase polymerase chain reaction, immunostaining and Western blotting revealed that arterial shear stress induced TGFβ / SMAD dependent in HUVEC which was regulated by TWIST 1&2 as the selective inhibition of TWIST 1 or 2 using specific siRNA suppressed EndMT in response to shear stress. We also noted that brief pretreatment of HUVECs with Dexamethasone can modulate EndMT changes in response to shear stress. Using spatial cell sequencing in human long saphenous vein segments exposed to acute arterial flow identified a cluster of cells that had both EC and SMC phenotypes where TWIST2 was significantly upregulated. We validated the untargeted spatial findings in segments of veins under acute arterial flow ex-vivo using comparative reverse-transcriptase polymerase chain reaction, immunostaining and RNAscope and observed that Dexamethasone can suppress EndMT changes in vein segments by suppressing TGFβ / SMAD/ TWIST1 &2.
Conclusion Dexamethasone brief pretreatment can suppress EndMT changes triggered by acute exposure of long saphenous vein segments to arterial haemodynamics by modulating TGFβ / SMAD / TWIST1 &2 pathway.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Van Geest foundation charitable fund and the BHF accelerator award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved under Leicester Biomedical Research Centre (BRICCS Ethics Ref: 09/H0406/114). Informed consent was obtained from all study participants prior to surgery and use of human tissue conformed to the principles outlined in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
